Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Kurt Miller

Showing results (211-220 of 290) with videos related to

Pageof 29
Sort By:
The Journal of Urology|January 22, 2008
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminomaStefan Hinz, Mark Schrader, Carsten Kempkensteffen, et al.
Therapeutics and Clinical Risk Management|September 14, 2020
Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMIHenning Plage, Poline Pielka, Lutz Liefeldt, et al.
The Prostate|January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump, Heather Payne, Kurt Miller, et al.
BJU International|November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyFritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
The Journal of Molecular Diagnostics : JMD|August 16, 2013
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcomeNadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
World Journal of Urology|June 10, 2016
Systemic therapy in metastatic renal cell carcinomaJens Bedke, Thomas Gauler, Viktor Grünwald, et al.
BJU International|April 11, 2018
Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE)Hannes Cash, Ursula Steiner, Axel Heidenreich, et al.
European Urology|February 27, 2007
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progressionMichael Lein, Manfred Wirth, Kurt Miller, et al.
World Journal of Urology|May 25, 2011
No need for systemic heparinization during laparoscopic donor nephrectomy with short warm ischemia timeFrank Friedersdorff, Ingmar Wolff, Serdar Deger, et al.
Prostate Cancer and Prostatic Diseases|August 23, 2018
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerationsE David Crawford, Axel Heidenreich, Nathan Lawrentschuk, et al.
Pageof 29

Showing results (211-220 of 290) with videos related to

Sort By:
Pageof 29
The Journal of Urology|January 22, 2008
The role of positron emission tomography in the evaluation of residual masses after chemotherapy for advanced stage seminomaStefan Hinz, Mark Schrader, Carsten Kempkensteffen, et al.
Therapeutics and Clinical Risk Management|September 14, 2020
Extended Criteria Donors in Living Kidney Transplantation Including Donor Age, Smoking, Hypertension and BMIHenning Plage, Poline Pielka, Lutz Liefeldt, et al.
The Prostate|January 29, 2011
Preliminary study of the specific endothelin a receptor antagonist zibotentan in combination with docetaxel in patients with metastatic castration-resistant prostate cancerDonald L Trump, Heather Payne, Kurt Miller, et al.
BJU International|November 17, 2009
Changes in alkaline phosphatase levels in patients with prostate cancer receiving degarelix or leuprolide: results from a 12-month, comparative, phase III studyFritz H Schröder, Bertrand Tombal, Kurt Miller, et al.
The Journal of Molecular Diagnostics : JMD|August 16, 2013
miRNA profiling identifies candidate mirnas for bladder cancer diagnosis and clinical outcomeNadine Ratert, Hellmuth-Alexander Meyer, Monika Jung, et al.
World Journal of Urology|June 10, 2016
Systemic therapy in metastatic renal cell carcinomaJens Bedke, Thomas Gauler, Viktor Grünwald, et al.
BJU International|April 11, 2018
Intermittent vs continuous docetaxel therapy in patients with metastatic castration-resistant prostate cancer - a phase III study (PRINCE)Hannes Cash, Ursula Steiner, Axel Heidenreich, et al.
European Urology|February 27, 2007
Serial markers of bone turnover in men with metastatic prostate cancer treated with zoledronic Acid for detection of bone metastases progressionMichael Lein, Manfred Wirth, Kurt Miller, et al.
World Journal of Urology|May 25, 2011
No need for systemic heparinization during laparoscopic donor nephrectomy with short warm ischemia timeFrank Friedersdorff, Ingmar Wolff, Serdar Deger, et al.
Prostate Cancer and Prostatic Diseases|August 23, 2018
Androgen-targeted therapy in men with prostate cancer: evolving practice and future considerationsE David Crawford, Axel Heidenreich, Nathan Lawrentschuk, et al.
Pageof 29